SCHEMBL2549846

SCHEMBL2549846

COc1ccc(CN(CCCCCOc2cc(F)c(F)cc2CO)C(=O)O)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
TSHR P16473 1/20 0.45
POLB P06746 2/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
F2 P00734 1/20 0.39
ELANE P08246 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NR1H3 Q13133 1/20 0.39
ACHE P22303 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 1/20 0.37
PDE10A Q9Y233 1/20 0.37
HCRTR2 O43614 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12282215 0.88 KDM4E (0.38) KDM4EALDH1A1TSHRPOLBMEN1
SCHEMBL2550348 0.82 ALDH1A1 (0.51) KDM4EALDH1A1TSHRPOLBMEN1
SCHEMBL2547103 0.79 ALDH1A1 (0.53) KDM4EALDH1A1TSHRPOLBMEN1
SCHEMBL15602928 0.79 ALDH1A1 (0.52) KDM4EALDH1A1TSHRPOLBMEN1
SCHEMBL2549487 0.78 GAA (0.38) KDM4EALDH1A1TSHRMEN1KMT2A
SCHEMBL2548974 0.77 ALDH1A1 (0.51) KDM4EALDH1A1TSHRPOLBMEN1
SCHEMBL2551664 0.76 ALDH1A1 (0.52) KDM4EALDH1A1TSHRPOLBMEN1
SCHEMBL2025290 0.69 CNR1 (0.46) KDM4EALDH1A1MEN1KMT2AF2
SCHEMBL12282460 0.69 MEN1 (0.43) KDM4EALDH1A1TSHRPOLBMEN1
SCHEMBL2017497 0.68 CNR2 (0.53) ALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716293-B2 Macrocyclic integrase inhibitors JANSSEN R&D IRELAND (IE) 2014-05-06 US disclosed
EP-2552923-B1 MACROCYCLIC INTEGRASE INHIBITORS JANSSEN R & D IRELAND (IE) 2014-03-26 EP disclosed
US-20130035341-A1 MACROCYCLIC INTEGRASE INHIBITORS JANSSEN R&D IRELAND (IE) 2013-02-07 US disclosed
EP-2552923-A1 MACROCYCLIC INTEGRASE INHIBITORS Janssen R&D Ireland (IE) 2013-02-06 EP disclosed
WO-2011121105-A1 MACROCYCLIC INTEGRASE INHIBITORS TIBOTEC PHARMACEUTICALS (IE) 2011-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035341-A1 MACROCYCLIC INTEGRASE INHIBITORS TYMP, PIM1, TYMS KDM4E 911/4885ALDH1A1 2328/4885TSHR 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.